# AIM (NCT02471391)

> ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

No report yet. It can be ordered.

- Drugs tested: venetoclax plus ibrutinib
- Indication: relapsed or refractory mantle cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02471391
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Peter MacCallum Cancer Centre, Australia
- Conditions: Mantle Cell Lymphoma
- Interventions: ABT-199; Ibrutinib
- Enrollment: 37
- Primary outcome: Complete response measured using IWG at 16 weeks

## Indexed commentary on AIM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- YouTube: 2
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=aim-nct02471391

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02471391", "email": "<work email>"}; the inbox owner confirms by the emailed link.